



MONITORING PRACTICES TO PROMOTE SAFER OPIOID USE

S HARE A PATIENT PROVIDER AGREEMENT (PPA) with clearly established boundaries and patient expectations PRIOR to initiating a trial of opioids for chronic non-cancer pain

- A PPA signed by both patient and provider and given to the patient is an important, convenient tool that can also **document patient counseling and education**.
- **Offering a PPA to all patients** regardless of a patient’s identified risk of opioid misuse and abuse **reduces stigma** and provides a minimal level of precaution/protection to prescriber and patient.
- There is no standard, validated, or legally binding form of a PPA; **consider inclusion of informed consent** (e.g., potential risks and benefits of an opioid trial, continuation, and discontinuation) **and plan of care** (e.g., goals of care and expectations, rights and responsibilities of provider and patient).

O PTIMIZE PATIENT TREATMENT (DRUG/NON-DRUG) USING A MULTI-DIMENSIONAL RATING SCALE to assess chronic pain, quality of life, and progress toward functional goals

- **The PEG** is a brief multi-functional measure of **Pain**, **E**njoyment of life, and **G**eneral activity **useful at baseline and at regular intervals** to assess and document patient response to treatment.
- **Set realistic expectations** that full pain relief is unlikely **and set individualized goals** that are Achievable, Recovery-related, and Measurable (A.R.M.); e.g., 15 minute daily walk.
- Continue or modify opioid treatment with demonstrated benefit and **discontinue when the risks** of side effects, misuse, addiction, and/or overdose **outweigh the benefit**.
- **Engage family and other key individuals when possible** to support patient-obtained information.

S CREEN FOR APPROPRIATE OPIOID USE AND THE CONTINUED NEED FOR OPIOID THERAPY, including prescription drug monitoring reports (e.g., SCRIPTS Narx Reports)

- **Assess and document risk of opioid misuse** with subjective and objective measures **PRIOR to prescribing**, and individualize level of monitoring and possible co-management to match the identified risk.
- **Review SCRIPTS Narx Reports at baseline and periodically** to help identify potential opioid misuse/abuse and support safe prescribing and dispensing.
- Continue to assess, monitor, and document risk of opioid misuse/abuse (including input from family members and key contacts) since **risk level can change for any patient at any point**.
- **Adjust ongoing monitoring plan** (e.g., SCRIPTS Narx Report Review, frequency of visits, urine drug tests, pill counts) **to match risk level** and co-manage or refer for addiction treatment as needed.



Prescriber Reports now display patient records for each metric when you log into in your SCRIPTS account.

CONSIDERATIONS FOR REVIEWING SOUTH CAROLINA PRESCRIPTION MONITORING PROGRAM (SCRIPTS) NARX REPORTS

A SCRIPTS Narx Report (also called a DHEC or PMP report) is one tool to help confirm a patient's controlled substance (C-II - C-IV) drug history, adherence, or potential drug abuse/misuse/diversion

WHAT IF:

APPARENTLY GOOD RESULTS (1 PHARMACY, 1 OPIOID PRESCRIBER)¹

- Does it match clinical evaluations (e.g., urine drug test) and patient interviews?
- Consider non-adherence behaviors not captured in results (e.g., bingeing, running out early).

WHAT IF:

TOTAL MORPHINE MILLIGRAM EQUIVALENTS PER DAY (MME/day)² SUGGESTS CONCERN FOR ADVERSE EVENTS OR OVERDOSE^{3,4,5}

- More recent guidelines recommend additional precautions when prescribing above dosing thresholds ranging from ≥ 50 MME/day to ≥ 120 MME/day.
- The CDC recommends to avoid, to carefully justify, or to consider specialist referral when prescribing doses ≥ 90 MME/day.
- SC Boards of Medical Examiners, Dentistry, Nursing, and Pharmacy Pain Guidelines agree with CDC recommendations.

Note: These guidelines do NOT recommend abrupt tapering or discontinuation of opioids at or above these thresholds. Carefully consider each patient situation prior to initiating a taper.

WHAT IF:

NARCOTIC NARX SCORE^{6,7} OR OVERDOSE RISK SCORE (ORS)⁸ SUGGESTS CONCERN FOR ADVERSE EVENTS OR OVERDOSE⁴

- Narcotic Narx Scores are indicators of opioid use and risk for adverse outcomes based on increased use.
- Suggested recommendations for ORS > 450 are intended to be comparable to those for patients prescribed at or above 50 MME/day; ORS > 650 comparable to those for patients prescribed at or above 90 MME/day.⁴
- Do scores match clinical evaluations (e.g., urine drug test) and patient interviews?
- Concerning scores should prompt a discussion with the patient and not a quick decision regarding medication continuation.

WHAT IF:

COMBINATION OF OPIOID AND OTHER CONTROLLED SUBSTANCE(S), ESPECIALLY BENZODIAZEPINES^{4,9,10}

- Pain guidelines concur benzodiazepines and opioids are high risk combinations, especially in the elderly; many recommend against combination unless clearly indicated.
- Is the combination clearly indicated? If clearly indicated, is the patient prescribed the lowest effective dose(s)?
- What is the patient's level of functioning?



For more information on tapering opioids and/or benzodiazepines visit: <https://msp.scdhhs.gov/tipsc/site-page/march-2018>

WHAT IF:

OPIOID-ACETAMINOPHEN COMBINATION PRODUCT

- Consider possibility that patient is taking other prescription medications or over-the-counter products containing acetaminophen.
- Counsel patient on risk of exceeding 4000 mg total daily acetaminophen dose or combining with alcohol.¹¹

Data suggest co-prescribing naloxone AND providing overdose education to patients, family, and friends encourages safer opioid use and reduces overdose rate.

WHAT IF:

POTENTIAL ABERRANT BEHAVIOR (2 OR MORE PHARMACIES, 2 OR MORE OPIOID PRESCRIBERS)³

- Does it match clinical evaluations (e.g., urine drug test) and patient interviews?
- Consider differential diagnosis for possible inappropriate opioid use:

- ADDICTION** - often characterized by behaviors that may include loss of control over drug use, craving, compulsive use, and continued use despite harm to health or relationships (See table at right)
Physical dependence and tolerance are normal physiologic adaptations to extended opioid therapy and are NOT the same as addiction.
- PHYSICAL DEPENDENCE** - biologic adaptation to drug that results in abstinence syndrome (signs and symptoms of withdrawal) upon cessation, rapid dose reduction and/or administration of antagonist
- TOLERANCE** - a physiologic state of reduced effect over time from regular drug exposure in which increased dosage is needed to produce specific effect (*increase in dose and no increase in effect may mean opioid is ineffective*)
- HYPERALGESIA** - increase in pain sensitivity that can be seen with rapid opioid dose escalation or high opioid dose (*consider if increase in pain with increase in dose*)
- PSEUDO-ADDICTION** - aberrant drug-related behaviors driven by uncontrolled pain (*relief seeking vs drug seeking*) that are reduced by improved pain control
- OTHER PSYCHIATRIC ILLNESSES** - such as anxiety, depression, PTSD, "chemical coping" (knowingly or unknowingly taking medications to decrease or numb negative emotions)
- DIVERSION** - moving medications from legal/medically indicated users to illegal/unauthorized users

CONCERNING BEHAVIORS FOR ADDICTION

- Requests for increases in opioid dose
- Requests for specific opioid by name, "brand name only" or allergic to all but the desired opioid
- Overwhelming focus on opioids during visits instead of underlying disease process
- Multiple office contacts regarding opioids
- Unwilling to follow through with recommended therapy/referrals (e.g., physical therapy)
- Running out early due to unsanctioned dose escalation
- Resistance to change therapy despite harm or negative consequences (e.g., over-sedation); unwilling to consider non-opioid therapy
- Concurrent alcohol or substance abuse
- Deterioration in function at home and work
- Opposition to monitoring (e.g., pill counts, UDT)
- Three or more requests for early refills
- Multiple "lost," "spilled" or "stolen" opioid prescriptions
- Multiple sources for opioids
- Illegal activities - forging prescriptions, selling opioid prescription
- Overdose

Adapted with permission: Boston University SCOPE of Pain Program www.scopeofpain.com

When patient behavior suggests concern for addiction, assess for Opioid Use Disorder (OUD). Patients with OUD often have poor outcomes when "kicked out" of care and typically respond better when care is "kicked up". OUD is a manageable chronic disease, just like hypertension or diabetes; **consider offering medication-assisted treatment (MAT)** or referral for treatment.



If you are interested in learning more about MAT at your practice, please visit <https://scmataaccess.com> and/or contact Rachel Grater at grater@muscc.edu

¹ Not all dispensed opioids require reporting to SCRIPTS, such as methadone dispensed from Opioid Treatment Programs (i.e., 'methadone clinics') or < 48 -hour supply from emergency department.
² Morphine Milligram Equivalents (MME) is a mathematical conversion that standardizes risk evaluation of the different opioids.
³ Increased risk of opioid overdose-related death has been associated with 4+ opioid prescriptions, 4+ pharmacies, or total MME/day ≥ 100 .
⁴ Consider co-prescribing naloxone.
⁵ Opioid overdose risk increases in a dose-response manner; dosages ≥ 50 total MME/day increase risks for overdose by at least 2 times the risk of dosages < 20 total MME/day.
⁶ The first two digits of the three-digit Narx Score is a 00-99 relative risk score and the last digit corresponds to the total number of potentially active opioid prescriptions.
⁷ All Narx Scores (i.e., Narcotic, Sedative, or Stimulant) include a 2-digit relative risk score and a count of potentially active prescriptions (i.e., opioids, sedatives or stimulants).
⁸ The Overdose Risk Score (ORS) indicates the relative risk of unintentional overdose death, the risk doubling with every 100 point increase (e.g., a score of 300 is two times the risk of 200, 500 is eight times the risk of 200).
⁹ Benzodiazepines and opioid medication labelings carry black box warnings highlighting the risks associated with concomitant use.
¹⁰ Lorazepam milligram equivalent (LME) values in SCRIPTS offer one way to compare sedative hypnotic medications for dose-related risk considerations.
¹¹ A maximum daily dose of 3000 mg should be considered, especially in patients with elevated liver function tests or known liver impairment.

REFERENCE LIST

- American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc*. 2009;57(8):1331-1346. doi:10.1111/j.1532-5415.2009.02376.x
- Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. *Am J Med*. 2006;119(4):292-296. doi:10.1016/j.amjmed.2005.09.019
- Gwira Baumbach JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. *JAMA Intern Med*. 2014;174(5):796-801. doi:10.1001/jamainternmed.2013.12711
- Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. *CMAJ*. 2017;189(18):E659-E666. doi:10.1503/cmaj.170363
- Calculating total daily dose of opioids for safer dosage. Centers for Disease Control and Prevention website. Updated August 28, 2019. Accessed May 26, 2020. <https://www.cdc.gov/drugoverdose/prescribing/guideline.html>
- Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain*. 2009;10(2):113-130. doi:10.1016/j.jpain.2008.10.008
- Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. *Ann Intern Med*. 2016;165(4):245-252. doi:10.7326/M15-2771
- Crawford C. CDC Warns of Misapplication of Its Opioid Guideline. American Academy of Family Physicians website. May 9, 2019. Accessed June 20, 2020. <https://www.aafp.org/news/health-of-the-public/20190509cdcopioidgdn.html>
- Herndon CM, Ray JB, M. Kominek C. Pain Management. In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11e. McGraw-Hill; 2020.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464
- Ducharme J, Moore S. Opioid use disorder assessment tools and drug screening. *Mo Med*. 2019;116(4):318-324.
- Opioid patient prescriber agreement. U.S. Food and Drug Administration website. 2012. Accessed May 26, 2020. <https://www.fda.gov/media/114694/download>
- Gifford JD, Anderson JE, Baley JM, et al. Guidelines for the Chronic Use of Opioid Analgesics. Federation of State Medical Boards website. April 2017. Accessed June 3, 2020. https://www.fsmbo.org/siteassets/advocacy/policies/opioid_guidelines_as_adopted_april-2017_final.pdf
- Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. *Pain Med*. 2005;6(2):107-112. doi:10.1111/j.1526-4637.2005.05031.x
- Hsu JR, Mir H, Wally MK, Seymour RB; Orthopaedic Trauma Association Musculoskeletal Pain Task Force. Clinical practice guidelines for pain management in acute musculoskeletal injury. *J Orthop Trauma*. 2019;33(5):e158-e182. doi:10.1097/BOT.0000000000001430
- Hurstak EE, Kushel M, Chang J, et al. The risks of opioid treatment: perspectives of primary care practitioners and patients from safety-net clinics. *Subst Abus*. 2017;38(2):213-221. doi:10.1080/08897077.2017.1296524
- Interagency Guideline on Prescribing Opioids for Pain. Washington State Agency Medical Directors' Group website. June 2015. Accessed June 3, 2020. <http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf>
- Kay C, Wozniak E, Ching A, Bernstein J. Pain agreements and healthcare utilization in a Veterans Affairs primary care population: a retrospective chart review. *Pain Ther*. 2018;7(1):121-126. doi:10.1007/s40122-018-0098-5
- Kirsh KL, Fishman SM. Multimodal approaches to optimize outcomes of chronic opioid therapy in the management of chronic pain. *Pain Med*. 2011;12 Suppl 1:S1-S11. doi:10.1111/j.1526-4637.2010.00992.x
- Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med*. 2009;24(6):733-738. doi:10.1007/s11606-009-0981-1
- Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. *Hepatology*. 2005;42(6):1364-1372. doi:10.1002/hep.20948
- Revised Journ Pain Management Guidelines. South Carolina Department of Labor, Licensing and Regulation website. July 28, 2017. Accessed June 15, 2020. <https://llr.sc.gov/med/pdf/FINAL%20Joint%20Revised%20Pain%20Management%20Guidelines%20August%202017.pdf>
- Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. *Pain Physician*. 2017;20(2S):S3-S92.
- Managing Chronic Non-Terminal Pain in Adults Including Prescribing Controlled Substances. University of Michigan Medicine website. Updated June 2017. Accessed June 3, 2020. <http://www.med.umich.edu/1info/FHP/practiceguides/pain/pain.pdf>
- Acetaminophen. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury website. Updated January 28, 2016. Accessed July 2020. <https://www.ncbi.nlm.nih.gov/books/NBK548162/>
- National Institute on Drug Abuse: Advancing Addiction Science [Internet]. Bethesda (MD): National Institutes of Health; c1992. NIDAMED: Medical & Health Professionals. [cited 2020 Mar]; [about 5 screens]. Available from: <https://www.drugabuse.gov/nidamed-medical-health-professionals>
- Rich RLC Jr. Prescribing opioids for chronic pain: unintended consequences of the 2016 CDC Guideline. *Am Fam Physician*. 2020;101(8):458-459.
- Naloxone for opioid safety: a provider's guide to prescribing naloxone to patients who use opioids. California Health Care Foundation website. January 2015. Accessed August 7, 2020. <https://www.chcf.org/wp-content/uploads/2017/12/PDF-NaloxoneOpioidSafetyProviders.pdf>
- Schottenfeld JR, Waldman SA, Gluck AR, Tobin DG. Pain and addiction in specialty and primary care: the bookends of a crisis. *J Law Med Ethics*. 2018;46(2):220-237. doi:10.1177/1073110518782923
- PMP AWARD™ South Carolina Prescription Drug Monitoring Program Requester User Support Manual Version 2.3. South Carolina Department of Health and Environmental Control website. February 2020. Accessed June 3, 2020. https://d1b1sd6x6nwlphm.cloudfront.net/aware/sc_aws_prod/narxcare_user_guide.pdf
- PMP AWARD™ South Carolina Prescription Drug Monitoring Program Data Submission Guide for Dispensers Version 2.1. South Carolina Department of Health and Environmental Control website. January 2020. Accessed May 20, 2020. <https://www.scdhec.gov/sites/default/files/media/document/sc-pmp-data-submission-dispenser-guide-Jan2020.pdf>
- FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. U.S. Food and Drug Administration website. August 31, 2016. Accessed June 4, 2020. <https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine>
- VA/DoD Clinical Practice Guidelines for Opioid Therapy for Chronic Pain Version 3.0. U.S. Department of Veterans Affairs website. February 2017. Accessed August 7, 2020. <https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf>
- Opioid use disorder: A VA clinician's guide to identification and management of opioid use disorder. U.S. Department of Veterans Affairs website. 2016. Accessed June 20, 2020. https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Opioid_Use_Disorder_Educational_Guide.pdf

WRITING GROUP

Writing Group (and Disclosures for Pharmaceutical Relationships): Sarah Ball, PharmD (none), Kelly Barth, DO (none), Sandra Counts, PharmD (none), Nancy Hahn, PharmD (none), Lauren Linder, PharmD (none), Jenna McCauley, PhD (none), Joseph McElwee, MD (none), William Moran, MD (none), Megan Pruitt, PharmD (none), Sophie Robert, PharmD (none), Chris Wisniewski, PharmD (none).

Acknowledgements: The MUSC College of Pharmacy houses SCORxE as a research and service center advancing the strategic initiative Building Healthy Communities. Chloe Cooper provided assistance with design and review. The MUSC Drug Information Center provided assistance with background research. Call 843.792.3896 or email druginfo@musc.edu for free access to MUSC's Drug Information Center to answer specific questions and requests from materials delivered.

The information contained in this summary is intended to assist primary care providers in the management of chronic non-cancer pain in adults in the primary care setting. This information is advisory only and is not intended to replace sound clinical judgement, nor should it be regarded as a substitute for individualized diagnosis and treatment. Special considerations are needed when treating some populations with certain conditions (such as respiratory/sleep disorders; cardiac, liver and renal impairment; debility; addiction; and pregnancy/breast-feeding).